# Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma

> **NCT03603847** · — · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 41 (actual)

## Conditions studied

- Anaplastic Large Cell Lymphoma, ALK-Positive

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03603847
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-02
- **Primary completion:** 2023-06-16
- **Final completion:** 2023-06-16
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-09-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03603847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03603847, "Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03603847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*